Bertel Jungin Aukio 1
Espoo 02600
Finland
358 9222 1195
https://herantis.com
版塊: Healthcare
行業: Biotechnology
全職員工: 10
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Antti Vuolanto D.Sc. (Tech) | Chief Executive Officer | 無 | 無 | 1975 |
Ms. Tone Kvale | Chief Financial Officer | 無 | 無 | 1969 |
Dr. Henri J. Huttunen Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
Mr. Jani Koskinen | Head of CMC | 無 | 無 | 無 |
Ms. Outi Lahdenperä M.D., Ph.D. | Chief Medical Ofcer | 無 | 無 | 無 |
Dr. Charlotte Videbaek M.D. | Clinical Consultant | 無 | 無 | 1962 |
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
截至 無 止,Herantis Pharma Oyj 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。